Stocks and Investing
Stocks and Investing
Mon, October 14, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Fri, October 11, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matthew Harrison Maintained (BLUE) at Hold with Decreased Target to $104 on, Oct 11th, 2019
Matthew Harrison of Morgan Stanley, Maintained "bluebird bio, Inc." (BLUE) at Hold with Decreased Target from $136 to $104 on, Oct 11th, 2019.
Matthew has made no other calls on BLUE in the last 4 months.
There are 3 other peers that have a rating on BLUE. Out of the 3 peers that are also analyzing BLUE, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Benjamin Burnett of "Stifel" Initiated at Hold and Held Target at $109 on, Tuesday, October 1st, 2019
These are the ratings of the 2 analyists that currently disagree with Matthew
- Jason McCarthy of "Maxim Group" Upgraded from Hold to Strong Buy and Held Target at $160 on, Tuesday, June 18th, 2019
- Matthew Luchini of "BMO Capital" Maintained at Buy with Decreased Target to $163 on, Monday, June 17th, 2019
Contributing Sources